Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Working closely with the University of British Columbia (UBC)'s Support Program to Advance Research Capacity (SPARC), MORU Malaria Researcher Dr Katherine Plewes was recently awarded a 3-year, C$971,551 grant for her study on Evaluating the renoprotective effect of acetaminophen in pediatric severe falciparum malaria: A randomized controlled trial.

Katherine Plewes

The study, a much larger version of Katherine’s earlier randomized controlled trial in adults with severe malaria in Chittagong, Bangladesh that showed that paracetamol improved kidney function and reduced the odds of developing Acute kidney injury (AKI), an important problem that contributes to an estimated 1.7 million deaths annually.

As children bear the major burden of malaria, Katherine’s study will test this protective effect in on African children, where AKI affects up to 45% of patients. With an ultimate goal to assess the role of paracetamol as a renoprotective adjunctive therapy in severe malaria, Katherine with Dr Caterina Fanello and the team at DR Congo will conduct at KIMORU, Kinshasa a randomized controlled trial of adjunctive paracetamol in 460 African children with severe malaria. The study  is expected to begin in September 2019.

Arjen Dondorp (MORU) is co-primary grant applicant. Dr. Caterina Fanello, Dr. Marie Onyamboko (both KIMORU), Prof Kevin Kain (University of Toronto), Dr. Adeera Levin (UBC) and Dr. Mavuto Mukaka (MORU) are co-applicants, and Prof John Oates (Vanderbilt University) is collaborator.

Similar stories

New antibiotic combination speeds recovery from severe scrub typhus, which infects 1 million people per year

Treating patients ill with severe scrub typhus – a life-threatening infection that kills tens of thousands of people a year - with a combination of intravenous antibiotics doxycycline and azithromycin is significantly more effective than the current monotherapy of using either drug alone, say researchers in a study published in the New England Journal of Medicine (NEJM).

Watch our webinar - Radical cure of vivax malaria: can we do better?

The three presentations and expert discussion by Dr Rob Commons, Dr Alison Roth and Dr James Watson, chaired by Professor Sir Nicholas White (Mahidol Oxford Research Unit) and Dr Chau Nguyen Hoang (Oxford University Clinical Research Unit), are now available.

Study supports evidence ivermectin not effective to treat COVID-19

21 Feb 2023 Oxford UK - High doses of the drug ivermectin, controversially recommended by some high-profile political and media figures during the COVID-19 pandemic, is ineffective at treating the COVID-19 virus, say University of Oxford-affiliated researchers in a study published today in eLife.

Phase II Malaria vaccine trial begins in Thailand

The Mahidol Oxford Tropical Medicine Research Unit (MORU) has begun a Phase II trial to demonstrate that R21/matrix M is well-tolerated and immunogenic when administered with the antimalarial drug combination.

Pilot study detects diverse DNA in ingredients of falsified tablets

A recent multidisciplinary pilot study, originating from LOMWRU and the Medicine Quality Research Group of IDDO and MORU, investigated whether bacterial, plant, fungal and animal DNA in the ingredients and from the environment (eDNA) could be detected from falsified (aka counterfeit) tablets.

Ricardo Aguas awarded Associate Professorship

We are delighted to announce that Ricardo Aguas has been awarded the Associate Professor title, in recognition of his achievements, contribution to teaching, and contribution to the general work of the Nuffield Department of Medicine.